Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 8,508 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasm Recurrent Clear all
Completed Phase 1Phase 2 Interventional

Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia

NCT00004898
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
Up to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Nov 4, 2026, 4:42 AM EST
Completed Phase 2 Interventional Results available

Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

NCT00068419
View directory record Official record
Conditions
Desmoid Tumor
Interventions
tamoxifen citrate, sulindac, laboratory biomarker analysis
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Nov 4, 2026, 4:42 AM EST
Terminated Phase 3 Interventional Results available

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

NCT02013167
View directory record Official record
Conditions
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Standard of Care Chemotherapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Nov 4, 2026, 4:42 AM EST
Completed Phase 2 Interventional

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

NCT00068432
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Celecoxib, Gemcitabine Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
11
States / cities
Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Nov 4, 2026, 4:42 AM EST
Not listed Phase 2 Interventional

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

NCT00003163
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, sargramostim, cyclophosphamide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Nov 4, 2026, 4:42 AM EST
Not listed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00002481
View directory record Official record
Conditions
Lymphoma
Interventions
cisplatin, cyclophosphamide, cytarabine, dexamethasone, etoposide, autologous bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Nov 4, 2026, 4:42 AM EST
Active, not recruiting Phase 2 Interventional

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCT05554328
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Selumetinib Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 229 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 4, 2026, 4:42 AM EST
Recruiting Phase 1 Interventional

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

NCT07332507
View directory record Official record
Conditions
Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Teclistamab
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
20
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 4, 2026, 4:42 AM EST
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

NCT00009763
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, monoclonal antibody m170, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody m170
Biological · Drug · Procedure + 1 more
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Nov 4, 2026, 4:42 AM EST
Terminated Phase 3 Interventional Results available

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

NCT01546571
View directory record Official record
Conditions
Melanoma
Interventions
POL-103A, POL-103A without API
Biological
Lead sponsor
Polynoma LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
59
States / cities
Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Nov 4, 2026, 4:42 AM EST
Completed Phase 1 Interventional

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

NCT02048709
View directory record Official record
Conditions
Solid Tumor
Interventions
GDC-0919
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Nov 4, 2026, 4:42 AM EST
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02227199
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Carboplatin, Etoposide, Ifosfamide, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 4, 2026, 4:42 AM EST
Active, not recruiting Phase 1 Interventional

Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

NCT04457232
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Prostate Gland, Prostate Carcinoma, Recurrent Prostate Carcinoma
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 4, 2026, 4:42 AM EST
Completed Phase 2 Interventional

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer

NCT01740336
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-0941, Placebo, Paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
47
States / cities
Sedona, Arizona • Anaheim, California • Encinitas, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Nov 4, 2026, 4:42 AM EST
Recruiting No phase listed Observational

Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy

NCT04957511
View directory record Official record
Conditions
Gynecologic Cancer, Immunotherapy, Gut Microbiome
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Nov 4, 2026, 4:42 AM EST
Terminated Phase 3 Interventional

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

NCT01009593
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular, Liver Diseases, Neoplasms by Histologic Type, Digestive System Neoplasms, Carcinoma, Liver Neoplasms, Neoplasms, Neoplasms by Site, Digestive System Diseases, Adenocarcinoma, Neoplasms, Glandular and Epithelial
Interventions
ABT-869, Sorafenib
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Beverly Hills, California • LaVerne, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Nov 4, 2026, 4:42 AM EST
Active, not recruiting Phase 1 Interventional

Surgical Nivolumab And Ipilimumab For Recurrent GBM

NCT04606316
View directory record Official record
Conditions
Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
Interventions
Nivolumab-Placebo, Nivolumab, Ipilimumab-Placebo, Ipilimumab, Surgery
Drug · Procedure
Lead sponsor
Gilbert Youssef
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 4, 2026, 4:42 AM EST
Completed Phase 2 Interventional Results available

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

NCT01091428
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma
Interventions
Alisertib, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
The Bronx, New York • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Nov 4, 2026, 4:42 AM EST
Completed Phase 2 Interventional Results available

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

NCT00963807
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Cisplatin, CT, Docetaxel, FDG, FLT, PET/CT, Surgery
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Nov 4, 2026, 4:42 AM EST
Not listed Phase 2 Interventional

Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma

NCT00033709
View directory record Official record
Conditions
Sarcoma
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Nov 4, 2026, 4:42 AM EST
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Anaplastic Oligodendroglioma

NCT00003465
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Nov 4, 2026, 4:42 AM EST
Active, not recruiting No phase listed Observational

Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT

NCT03846167
View directory record Official record
Conditions
Breast Cancer
Interventions
Imaging Drug FluorThanatrace (FTT)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 4, 2026, 4:42 AM EST
Completed Phase 2 Interventional Results available

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

NCT00022698
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine, Irinotecan
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
17
States / cities
Birmingham, Alabama • Loma Linda, California • Norwich, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Nov 4, 2026, 4:42 AM EST
Completed Phase 2 Interventional Results available

Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine

NCT00365144
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Nov 4, 2026, 4:42 AM EST